Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
BURLINGTON, Mass., March 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7, 2016 at 2:00 p.m. EST at the at the Boston Marriott Copley Place.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
